Mechanism for Biphasic Rel A. NF-kappaB1 Nuclear Translocation in Tumor Necrosis Factor Alpha-stimulated Hepatocytes
Overview
Authors
Affiliations
The proinflammatory cytokine, tumor necrosis factor alpha (TNFalpha), is a potent activator of angiotensinogen gene transcription in hepatocytes by activation of latent nuclear factor-kappaB (NF-kappaB) DNA binding activity. In this study, we examine the kinetics of TNFalpha-activated translocation of the 65-kDa (Rel A) and 50-kDa (NF-kappaB1) NF-kappaB subunits mediated by inhibitor (IkappaB) proteolysis in HepG2 hepatoblastoma cells. HepG2 cells express the IkappaB members IkappaBalpha, IkappaBbeta, and IkappaBgamma. In response to TNFalpha, Rel A.NF-kappaB1 translocation and DNA binding activity follows a biphasic profile, with an "early" induction (15-30 min), followed by a nadir to control levels at 60 min, and a "late" induction (>120 min). The early phase of Rel A.NF-kappaB1 translocation depends on simultaneous proteolysis of both IkappaBalpha and IkappaBbeta isoforms; IkappaBgamma is inert to TNFalpha treatment. The 60-min nadir is due to a rapid IkappaBalpha resynthesis that reassociates with Rel A and completely inhibits its DNA binding activity; the 60-min nadir is not observed when IkappaBalpha resynthesis is prevented by cycloheximide treatment. By contrast, selective inhibition of IkappaBbeta proteolysis by pretreatment of HepG2 cells with the peptide aldehyde N-acetyl-Leu-Leu-norleucinal completely blocks the late phase of Rel A.NF-kappaB1 translocation. These studies indicate the presence of inducible and constitutive cytoplasmic NF-kappaB pools in hepatocytes. TNFalpha induces a coordinated proteolysis and resynthesis of IkappaB isoforms to produce dynamic changes in NF-kappaB nuclear abundance.
Arroyo Almenas F, Toro G, Szaniszlo P, Maskey M, Thanki K, Koltun W Antioxidants (Basel). 2024; 13(9).
PMID: 39334726 PMC: 11428476. DOI: 10.3390/antiox13091067.
Liu Y, Trnka M, He L, Burlingame A, Correia M Mol Cell Proteomics. 2023; 22(2):100495.
PMID: 36634736 PMC: 9947424. DOI: 10.1016/j.mcpro.2023.100495.
Liu Y, Trnka M, Guan S, Kwon D, Kim D, Chen J Mol Cell Proteomics. 2020; 19(12):1968-1986.
PMID: 32912968 PMC: 7710137. DOI: 10.1074/mcp.RA120.002316.
Zhang J, Shangguan Z, Chen C, Zhang H, Lin Y Drug Des Devel Ther. 2016; 10:1829-35.
PMID: 27330276 PMC: 4896467. DOI: 10.2147/DDDT.S104602.
Qin J, Fang N, Lou J, Zhang W, Xu S, Liu H PLoS One. 2014; 9(5):e96089.
PMID: 24824999 PMC: 4019472. DOI: 10.1371/journal.pone.0096089.